Company Description
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.
Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system.
The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names.
It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors.
TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
| Country | United States |
| Founded | 2008 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Marlan Walker |
Contact Details
Address: 951 Yamato Road, Suite 220 Boca Raton, Florida 33431 United States | |
| Phone | 561-961-1900 |
| Website | therapeuticsmd.com |
Stock Details
| Ticker Symbol | TXMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000025743 |
| CUSIP Number | 88338N206 |
| ISIN Number | US88338N2062 |
| Employer ID | 87-0233535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marlan D. Walker J.D. | Chief Executive Officer |
| Joseph A. Ziegler | Principal Financial and Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| Apr 6, 2026 | SCHEDULE 13G | Filing |
| Apr 1, 2026 | 10-K/A | [Amend] Annual report |
| Apr 1, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 10-K | Annual Report |
| Jan 21, 2026 | 8-K | Current Report |
| Dec 16, 2025 | 8-K | Current Report |
| Nov 13, 2025 | 8-K | Current Report |